These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

532 related articles for article (PubMed ID: 21620777)

  • 1. Cell autonomous role of PTEN in regulating castration-resistant prostate cancer growth.
    Mulholland DJ; Tran LM; Li Y; Cai H; Morim A; Wang S; Plaisier S; Garraway IP; Huang J; Graeber TG; Wu H
    Cancer Cell; 2011 Jun; 19(6):792-804. PubMed ID: 21620777
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of dietary polyunsaturated fatty acids on castration-resistant Pten-null prostate cancer.
    Wang S; Wu J; Suburu J; Gu Z; Cai J; Axanova LS; Cramer SD; Thomas MJ; Perry DL; Edwards IJ; Mucci LA; Sinnott JA; Loda MF; Sui G; Berquin IM; Chen YQ
    Carcinogenesis; 2012 Feb; 33(2):404-12. PubMed ID: 22159221
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The steroid receptor coactivator-3 is required for the development of castration-resistant prostate cancer.
    Tien JC; Liu Z; Liao L; Wang F; Xu Y; Wu YL; Zhou N; Ittmann M; Xu J
    Cancer Res; 2013 Jul; 73(13):3997-4008. PubMed ID: 23650284
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Resveratrol regulates the PTEN/AKT pathway through androgen receptor-dependent and -independent mechanisms in prostate cancer cell lines.
    Wang Y; Romigh T; He X; Orloff MS; Silverman RH; Heston WD; Eng C
    Hum Mol Genet; 2010 Nov; 19(22):4319-29. PubMed ID: 20729295
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High Efficacy of Combination Therapy Using PI3K/AKT Inhibitors with Androgen Deprivation in Prostate Cancer Preclinical Models.
    Marques RB; Aghai A; de Ridder CMA; Stuurman D; Hoeben S; Boer A; Ellston RP; Barry ST; Davies BR; Trapman J; van Weerden WM
    Eur Urol; 2015 Jun; 67(6):1177-1185. PubMed ID: 25220373
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LncRNA PCAT1 activates AKT and NF-κB signaling in castration-resistant prostate cancer by regulating the PHLPP/FKBP51/IKKα complex.
    Shang Z; Yu J; Sun L; Tian J; Zhu S; Zhang B; Dong Q; Jiang N; Flores-Morales A; Chang C; Niu Y
    Nucleic Acids Res; 2019 May; 47(8):4211-4225. PubMed ID: 30773595
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CBP loss cooperates with PTEN haploinsufficiency to drive prostate cancer: implications for epigenetic therapy.
    Ding L; Chen S; Liu P; Pan Y; Zhong J; Regan KM; Wang L; Yu C; Rizzardi A; Cheng L; Zhang J; Schmechel SC; Cheville JC; Van Deursen J; Tindall DJ; Huang H
    Cancer Res; 2014 Apr; 74(7):2050-61. PubMed ID: 24491799
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PTEN, NHERF1 and PHLPP form a tumor suppressor network that is disabled in glioblastoma.
    Molina JR; Agarwal NK; Morales FC; Hayashi Y; Aldape KD; Cote G; Georgescu MM
    Oncogene; 2012 Mar; 31(10):1264-74. PubMed ID: 21804599
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual targeting of androgen receptor and mTORC1 by salinomycin in prostate cancer.
    Mirkheshti N; Park S; Jiang S; Cropper J; Werner SL; Song CS; Chatterjee B
    Oncotarget; 2016 Sep; 7(38):62240-62254. PubMed ID: 27557496
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PTEN and PHLPP crosstalk in cancer cells and in TGFβ-activated stem cells.
    Ghalali A; Ye ZW; Högberg J; Stenius U
    Biomed Pharmacother; 2020 Jul; 127():110112. PubMed ID: 32294598
    [TBL] [Abstract][Full Text] [Related]  

  • 11. AKT-mediated stabilization of histone methyltransferase WHSC1 promotes prostate cancer metastasis.
    Li N; Xue W; Yuan H; Dong B; Ding Y; Liu Y; Jiang M; Kan S; Sun T; Ren J; Pan Q; Li X; Zhang P; Hu G; Wang Y; Wang X; Li Q; Qin J
    J Clin Invest; 2017 Apr; 127(4):1284-1302. PubMed ID: 28319045
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patient-derived Hormone-naive Prostate Cancer Xenograft Models Reveal Growth Factor Receptor Bound Protein 10 as an Androgen Receptor-repressed Gene Driving the Development of Castration-resistant Prostate Cancer.
    Hao J; Ci X; Xue H; Wu R; Dong X; Choi SYC; He H; Wang Y; Zhang F; Qu S; Zhang F; Haegert AM; Gout PW; Zoubeidi A; Collins C; Gleave ME; Lin D; Wang Y
    Eur Urol; 2018 Jun; 73(6):949-960. PubMed ID: 29544736
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human heterochromatin protein 1 isoform HP1beta enhances androgen receptor activity and is implicated in prostate cancer growth.
    Shiota M; Song Y; Yokomizo A; Tada Y; Kuroiwa K; Eto M; Oda Y; Inokuchi J; Uchiumi T; Fujimoto N; Seki N; Naito S
    Endocr Relat Cancer; 2010 Jun; 17(2):455-67. PubMed ID: 20308360
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phosphatidylinositol 3-kinase/Akt stimulates androgen pathway through GSK3beta inhibition and nuclear beta-catenin accumulation.
    Sharma M; Chuang WW; Sun Z
    J Biol Chem; 2002 Aug; 277(34):30935-41. PubMed ID: 12063252
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conditional expression of PTEN alters the androgen responsiveness of prostate cancer cells.
    Wu Z; Conaway M; Gioeli D; Weber MJ; Theodorescu D
    Prostate; 2006 Jul; 66(10):1114-23. PubMed ID: 16637073
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytosolic phospholipase A2α sustains pAKT, pERK and AR levels in PTEN-null/mutated prostate cancer cells.
    Hua S; Yao M; Vignarajan S; Witting P; Hejazi L; Gong Z; Teng Y; Niknami M; Assinder S; Richardson D; Dong Q
    Biochim Biophys Acta; 2013 Jun; 1831(6):1146-57. PubMed ID: 23500889
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SKP2 loss destabilizes EZH2 by promoting TRAF6-mediated ubiquitination to suppress prostate cancer.
    Lu W; Liu S; Li B; Xie Y; Izban MG; Ballard BR; Sathyanarayana SA; Adunyah SE; Matusik RJ; Chen Z
    Oncogene; 2017 Mar; 36(10):1364-1373. PubMed ID: 27869166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterizing the contribution of stem/progenitor cells to tumorigenesis in the Pten-/-TP53-/- prostate cancer model.
    Abou-Kheir WG; Hynes PG; Martin PL; Pierce R; Kelly K
    Stem Cells; 2010 Dec; 28(12):2129-40. PubMed ID: 20936707
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New therapeutic approach to suppress castration-resistant prostate cancer using ASC-J9 via targeting androgen receptor in selective prostate cells.
    Lai KP; Huang CK; Chang YJ; Chung CY; Yamashita S; Li L; Lee SO; Yeh S; Chang C
    Am J Pathol; 2013 Feb; 182(2):460-73. PubMed ID: 23219429
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of the androgen receptor as a novel mechanism of taxol chemotherapy in prostate cancer.
    Gan L; Chen S; Wang Y; Watahiki A; Bohrer L; Sun Z; Wang Y; Huang H
    Cancer Res; 2009 Nov; 69(21):8386-94. PubMed ID: 19826044
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.